EMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum
The PD-1 antibody cemiplimab lengthened survival compared with single-agent chemotherapy in recurrent cervical cancer after platinum, regardless of PD-L1 expression, the first immunotherapy to show a survival benefit in this disease.
Overview
Phase 3 trial of 608 patients with recurrent cervical cancer progressing after first-line platinum chemotherapy randomised to cemiplimab or investigator's choice single-agent chemotherapy, enrolled irrespective of PD-L1 status.
Median overall survival was 12.0 versus 8.5 months (hazard ratio 0.69) overall and 11.1 versus 8.8 months in squamous cell carcinoma; response was 16.4 versus 6.3 percent, and benefit was seen across PD-L1 levels.
- Median overall survival 12.0 vs 8.5 months; hazard ratio 0.69.
- Objective response 16.4 percent vs 6.3 percent.
Cemiplimab is an option for second-line cervical cancer in patients who have not had immunotherapy, though most now receive pembrolizumab first line, moving cemiplimab later or out of sequence.
- Patients were immunotherapy-naive; applicability after first-line pembrolizumab is unclear.
Similar pages
not linked directly; found by shared links- Key paperGOG 240: bevacizumab added to chemotherapy for advanced cervical cancer
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
- Key paperC-POST: adjuvant cemiplimab versus placebo in high-risk cutaneous squamous cell carcinoma
- Key paperNeoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma
- Key paperKEYNOTE-826: pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
- Key paperinnovaTV 301: tisotumab vedotin versus chemotherapy as second- or third-line therapy for recurrent cervical cancer
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
- Key paperPD-1 blockade with cemiplimab in advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1)